Literature DB >> 25864172

Local failure in parameningeal rhabdomyosarcoma correlates with poor response to induction chemotherapy.

Matthew M Ladra1, Henry C Mandeville2, Andrzej Niemierko1, Timothy P Padera1, Alison M Friedmann1, Shannon M MacDonald1, David Ebb1, Yen-Lin Chen1, Nancy J Tarbell1, Torunn I Yock3.   

Abstract

BACKGROUND: Local control remains a challenge in pediatric parameningeal rhabdomyosarcoma (PM-RMS), and survival after local failure (LF) is poor. Identifying patients with a high risk of LF is of great interest to clinicians. In this study, we examined whether tumor response to induction chemotherapy (CT) could predict LF in embryonal PM-RMS.
METHODS: We identified 24 patients with embryonal PM-RMS, age 2 to 18 years, with complete magnetic resonance imaging and gross residual disease after surgical resection. All patients received proton radiation therapy (RT), median dose 50.4 GyRBE (50.4-55.8 GyRBE). Tumor size was measured before initial CT and before RT.
RESULTS: With a median follow-up time of 4.1 years for survivors, LF was seen in 9 patients (37.5%). The median time from the initiation of CT to the start of RT was 4.8 weeks. Patients with LF had a similar initial (pre-CT) tumor volume compared with patients with local controlled (LC) (54 cm(3) vs 43 cm(3), P=.9) but a greater median volume before RT (pre-RT) (40 cm(3) vs 7 cm(3), P=.009) and a smaller median relative percent volume reduction (RPVR) in tumor size (0.4% vs 78%, P<.001). Older age (P=.05), larger pre-RT tumor volume (P=.03), and smaller RPVR (P=.003) were significantly associated with actuarial LF on univariate Cox analysis.
CONCLUSIONS: Poor response to induction CT appears to be associated with an increased risk of LF in pediatric embryonal PM-RMS.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25864172      PMCID: PMC5479480          DOI: 10.1016/j.ijrobp.2015.01.049

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  31 in total

1.  In regard to Donaldson et al: results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma-a report from the IRSG. IJROBP 2001;51:718-728.

Authors:  Robert D Timmerman; Marc Mendonca
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-12-01       Impact factor: 7.038

2.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

3.  MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals.

Authors:  Francesco Marampon; Giovanni Luca Gravina; Agnese Di Rocco; Pierluigi Bonfili; Mario Di Staso; Caterina Fardella; Lorella Polidoro; Carmela Ciccarelli; Claudio Festuccia; Vladimir M Popov; Richard G Pestell; Vincenzo Tombolini; Bianca Maria Zani
Journal:  Mol Cancer Ther       Date:  2011-01       Impact factor: 6.261

4.  Tumour volume reduction after neoadjuvant chemotherapy impacts outcome in localised embryonal rhabdomyosarcoma.

Authors:  Tobias M Dantonello; Monika Stark; Beate Timmermann; Jörg Fuchs; Barbara Selle; Christin Linderkamp; Rupert Handgretinger; Rudolf Hagen; Simone Feuchtgruber; Stefanie Kube; Daniel Kosztyla; Bernarda Kazanowska; Ruth Ladenstein; Felix Niggli; Gustaf Ljungman; Stefan S Bielack; Thomas Klingebiel; Ewa Koscielniak
Journal:  Pediatr Blood Cancer       Date:  2014-09-27       Impact factor: 3.167

5.  Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North American and European cooperative groups.

Authors:  J H M Merks; G L De Salvo; C Bergeron; G Bisogno; A De Paoli; A Ferrari; A Rey; O Oberlin; M C G Stevens; A Kelsey; J Michalski; D S Hawkins; J R Anderson
Journal:  Ann Oncol       Date:  2014-01       Impact factor: 32.976

6.  Rhabdomyosarcoma of head and neck in children. Combination treatment by surgery, irradiation, and chemotherapy.

Authors:  S S Donaldson; J R Castro; J R Wilbur; R H Jesse
Journal:  Cancer       Date:  1973-01       Impact factor: 6.860

7.  Preliminary results of a phase II trial of proton radiotherapy for pediatric rhabdomyosarcoma.

Authors:  Matthew M Ladra; Jackie D Szymonifka; Anita Mahajan; Alison M Friedmann; Beow Yong Yeap; Claire P Goebel; Shannon M MacDonald; David R Grosshans; Carlos Rodriguez-Galindo; Karen J Marcus; Nancy J Tarbell; Torunn I Yock
Journal:  J Clin Oncol       Date:  2014-10-20       Impact factor: 44.544

8.  Comparison of the prognostic value of assessing tumor diameter versus tumor volume at diagnosis or in response to initial chemotherapy in rhabdomyosarcoma.

Authors:  Andrea Ferrari; Rosalba Miceli; Cristina Meazza; Michela Casanova; Francesca Favini; Carlo Morosi; Giovanna Trecate; Alfonso Marchianò; Roberto Luksch; Graziella Cefalo; Monica Terenziani; Filippo Spreafico; Daniela Polastri; Marta Podda; Serena Catania; Elisabetta Schiavello; Patrizia Giannatempo; Lorenza Gandola; Maura Massimino; Luigi Mariani
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

9.  Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children's Oncology Group.

Authors:  Abby R Rosenberg; James R Anderson; Elizabeth Lyden; David A Rodeberg; Suzanne L Wolden; Simon C Kao; David M Parham; Carola Arndt; Douglas S Hawkins
Journal:  Eur J Cancer       Date:  2013-12-18       Impact factor: 9.162

10.  Radiation therapy for rhabdomyosarcoma: local failure risk for Clinical Group III patients on Intergroup Rhabdomyosarcoma Study II.

Authors:  M D Wharam; J J Hanfelt; M C Tefft; J Johnston; L G Ensign; J Breneman; S S Donaldson; C Fryer; E A Gehan; R B Raney; H M Maurer
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-07-01       Impact factor: 7.038

View more
  3 in total

1.  Worse Outcomes for Head and Neck Rhabdomyosarcoma Secondary to Reduced-Dose Cyclophosphamide.

Authors:  Dana L Casey; Leonard H Wexler; Suzanne L Wolden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-11-30       Impact factor: 7.038

Review 2.  Current management of pediatric soft tissue sarcomas.

Authors:  Surasak Sangkhathat
Journal:  World J Clin Pediatr       Date:  2015-11-08

3.  Excessive Treatment Failures in Patients With Parameningeal Rhabdomyosarcoma With Reduced-dose Cyclophosphamide and Delayed Radiotherapy.

Authors:  John T Lucas; Alberto S Pappo; Jianrong Wu; Daniel J Indelicato; Matthew J Krasin
Journal:  J Pediatr Hematol Oncol       Date:  2018-07       Impact factor: 1.170

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.